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ABSTRACT OF THESIS

THE INTERACTIVE EFFECTS OF BRAIN-DERIVED NEUROTROPHIC FACTOR
(BDNF) POLYMORPHISMS AND POSTTRAUMATIC STRESS DISORDER ON
NEUROCOGNITIVE FUNCTIONING IN U.S. MILITARY VETERANS
Posttraumatic Stress Disorder (PTSD) is associated with mild-to-moderate deficits
in neurocognitive functioning. Single nucleotide polymorphisms (SNPs) in the brainderived neurotrophic factor (BDNF) gene, namely, the Met allele, may also be associated
with mild deficits in neurocognitive functioning. However, findings are inconsistent and
may be sensitive to environmental epigenetic moderators such as psychopathology.
The current study analyzed data from European-American U.S. military veterans
(n = 1,244) who participated in the 2011 National Health and Resilience in Veterans
Study (NHRVS). Multivariate analyses of covariances were conducted to evaluate the
unique and interactive effects of the Met allele and probable PTSD on objective and
subjective neurocognitive functioning.
Significant (p ≤ .001) interactions between Met allele carrier status and probable
PTSD were observed in objective (ηp2 = .028) and subjective neurocognitive functioning
(ηp2 = .029). In individuals without PTSD (n = 1113), the Met allele was not significantly
associated with objective neurocognitive functioning (p = .01, ηp2 = .013) or subjective
neurocognitive functioning (p = .17, ηp2 = .009). In individuals with PTSD (n = 131), the
Met allele was significantly (p < .01) associated with poorer objective (ηp2 = .179) and
subjective neurocognitive functioning (ηp2 = .237).
These findings suggest that associations between the Met allele and
neurocognitive functioning are dependent on the presence of PTSD.
KEYWORDS: BDNF, neurocognition, PTSD, veterans, epigenetics
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CHAPTER 1. INTRODUCTION
Posttraumatic Stress Disorder (PTSD) is a psychiatric disorder that can develop
following exposure to traumatic event(s) involving actual or threatened death, serious
injury, or sexual assault (American Psychiatric Association [APA], 2013). Characteristic
symptoms of PTSD include trauma-related intrusions, avoidance of trauma-related
stimuli, negative alterations in cognition and mood, and intensification of emotional
arousal and reactivity (APA, 2013). Upwards of 89% of the population will experience
trauma during their life (Goldstein et al., 2016; Kilpatrick et al., 2013) but the lifetime
and 12-month prevalence of PTSD in the general population are 8% and 4%, respectively
(Goldstein et al., 2016; Kilpatrick et al., 2013; Smith et al., 2016). Overall prevalence
estimates are higher among groups that are more likely to encounter traumatic events
than the general population, such as combat veterans and emergency health professionals
(Iranmanesh et al., 2013; Smith et al., 2016; Weiss et al., 1992).
Neurocognitive Functioning and Posttraumatic Stress Disorder
A diagnosis of PTSD and PTSD symptomatology are associated with mild to
moderate deficits in cognitive functioning (Gilbertson et al., 2001; Uddo et al.,1993). A
meta-analysis involving 60 cross-sectional studies found that individuals with PTSD
exhibited poorer verbal learning, processing speed, working memory, and verbal memory
(Cohen’s ds = .20 to .62) compared to trauma-exposed but psychiatrically healthy
participants (Scott et al., 2015). Additionally, veterans with PTSD report poorer
subjective neurocognitive functioning than trauma-exposed veterans without PTSD
(Averill et al., 2019; Spencer et al., 2010).
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Although deficits in neurocognitive functioning were originally thought to result
from trauma exposure (Everly & Horton, 1989; Uddo et al., 1993), it is likely that trauma,
PTSD symptoms, and neurocognitive functioning are reciprocally related to one another
(Brewin, 2007; Brewin et al., 2010; McNally, 2006; Qureshi et al., 2011). Individuals
with PTSD exhibit poorer learning and memory than psychiatrically healthy controls,
even after controlling for pre-trauma IQ (Gil et al., 1990). Similarly, after adjusting for
estimated pre-military IQ, working memory and sustained attention functioning were
negatively correlated with PTSD severity in U.S. (United States) military veterans
(Vasterling et al., 2002). Longitudinal research has shown that working memory, verbal
intelligence, and processing speed performance among young adults (20-28 years old)
prior to a natural disaster were inversely associated with re-experiencing and arousal
symptoms three to eight months following the trauma (Parslow & Jorm, 2007). Similarly,
pre-deployment immediate visual recall and verbal memory predicted post-deployment
PTSD severity among U.S. military veterans (Marx et al., 2009). Taken together, the
available literature suggests that neurocognitive deficits prior to a traumatic event may
serve as a possible risk factor for the development of PTSD and is exacerbated by PTSD
itself.
Brain-Derived Neurotrophic Factor Polymorphisms
Genetic research has identified multiple characteristics that can increase risk for
neurocognitive deficits and accelerated age-related neurocognitive decline. Genetic
characteristics such as the Apolipoprotein E ε4 gene, chromosome 14q24 presenilin-1
mutation, and amyloid precursor protein mutations have been associated with
exacerbated age-related neurocognitive decline and Alzheimer’s Disease (Hersi et al.,
2017; Scapagnini, 2010; Tilley et al., 1998). Similarly, genetic polymorphisms on the
2

brain-derived neurotrophic factor (BDNF) gene are associated with neurocognitive
deficits (Azeredo et al., 2017; Egan et al., 2003; Kennedy et al., 2015; Miyajima et al.,
2008).
Brain-derived neurotrophic factor is a protein within the neurotrophin family
located in the short (p) arm of chromosome 11 at position 14.1. It supports neuron
differentiation, maintenance, and maturation (Bathina & Das, 2015). It has also shown
neuroprotective effects against adverse neural conditions such as glutamatergic
overstimulation and hypoglycemia (Maisonpierre et al., 1991). Brain-derived
neurotrophic factor also regulates neural plasticity, such as axonal, dendritic, and synaptic
growth (Bramham & Messaoudi, 2005; Calabrese et al., 2014; Lu et al., 2005).
Accordingly, BDNF plays an important role in plasticity processes in several brain
regions that are important to neurocognitive functioning, such as the hippocampus,
striatum, and prefrontal cortex (Bath et al., 2012; Brigadski & Lessmann, 2014; Jing et
al., 2017; Linnarsson et al., 1997; Notaras et al., 2017; Pattwell et al., 2012).
Common polymorphisms occur on the BDNF gene. These variations occur due to
single nucleotide transitions from guanine to adenine at position 196 in exon 5 (rs6265;
Cargill et al., 1999). This single nucleotide polymorphism (SNP), results in a substitution
at the 66th codon from valine (Val) to methionine (Met). Because the substitution is
genetic, this polymorphism can be inherited. As such, there are two opportunities for
progeny to inherit this SNP: one from the mother and the other from the father. Possible
genotypes include Val66Val (both standard alleles), Val66Met (one standard allele and
one with rs6265), and Met66Met (both alleles with rs6265; Lichtblau, 2010). The
frequency of the Met allele varies from 0 – 72% depending on geographic region and
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ethnicity (Petryshen et al., 2010). For example, the frequency of the Met allele varies
from 15% to 18% among white European-Americans (Hori et al., 2020; Zhang et al.,
2006) to over 45% in Cambodia (Petryshen et al., 2010).
PTSD and BDNF Polymorphisms
Cross-sectional studies suggest that carriers of the Met allele are at an increased
risk for PTSD compared to homozygote Val allele counterparts (Bruenig et al., 2016; Li
et al., 2016; Zhang et al., 2014; Zhang et al., 2016); though not all studies have reported
significant associations (Bountress et al., 2017; Lee et al., 2006). Research also suggests
that Met allele carriers report more severe PTSD symptom severity than non-Met carriers
(Pitts et al., 2019). Further, the Met allele may help explain the variance between
responders and non-responders to behavioral (Felmingham et al., 2013) and
pharmacological intervention for PTSD (Malikowska-Racia & Salat, 2019). Together,
these data suggest that the Met allele may influence the etiology, maintenance, and
treatment of PTSD symptomatology for some trauma-exposed individuals.
BDNF and Neurocognitive Functioning
Human studies investigating the associations between BDNF SNPs and
neurocognitive functioning have yielded mixed results. Some studies found that, relative
to non-Met carriers, Met carriers exhibited poorer attentional capacities, processing
speed, and memory performance (Azeredo et al., 2017; Egan et al., 2003; McAllister et
al., 2012; Miyajima et al., 2008). Furthermore, some studies suggest that the Met allele
adversely impacts self-reported neurocognitive functioning (Pitts et al., 2020). Other
studies found no associations between the Met allele and objective attentional capacities,
processing speed, and memory performance (Benjamin et al., 2010; Karnik et al., 2010;
Mandelman & Grigorenko, 2012). One study even reported better objective
4

neurocognitive functioning among Met allele carriers compared to non-Met carriers
(Alfimova et al., 2012). These inconsistencies can be partly attributed to study
limitations; lower statistical power, heterogeneous samples, and neurocognitive measures
with psychometric shortcomings (Mandelman & Grigorenko, 2012). Most studies did not
control for or model important individual differences that may also affect neurocognitive
functioning (Alfimova et al., 2012; Benjamin et al., 2010; Egan et al., 2003; Karnik et al.,
2010). This includes, but is not limited to education level, stress and trauma exposure,
and psychopathology, including PTSD (Boals & Banks, 2012; van Hooren et al., 2007;
Inzelberg et al., 2007; Leibovici et al., 1996; Scott et al., 2015).
Environmental Epigenetic Factors and BDNF Polymorphisms
Environmental factors can modify gene expression without altering the
underlying genetic sequence to impact phenotypic expression in a process known as
epigenetics (McEwen, 2016). The most well-understood epigenetic mechanism is DNA
methylation (Ho et al., 2012). Methylation occurs when a methyl group is added to the 5’
position of a gene sequence on the promoter region – a region that controls upregulation
or suppression of gene transcription – by an enzyme called methyltransferase (Moore, Le,
& Fan, 2013). When a promoter region becomes methylated, the ribonucleic acid
polymerase – the enzyme that initiates gene transcription – cannot bind to the DNA
strand, thus preventing protein manufacturing (Moore, Le, & Fan, 2013). The methyl
group will remain on the gene until it is removed or altered by an enzyme (Moore, Le, &
Fan, 2013).
Gene methylation allows cells to adapt to different environmental stimuli and
modify cellular functions. For example, methylation is important for energy conservation;
allowing cells to silence genes and allocate resources elsewhere when needed (Varriale,
5

2014). Although gene methylation serves an adaptive function, methylation is sustained
after meiotic division and therefore can have long-lasting effects (Hitchins & Ward,
2007). As such, high frequency and long-term exposure to adverse cellular or
environmental stimuli can have longstanding consequences on gene expression.
Environmental factors such as exposure to tobacco smoke, infectious pathogens,
infectious fungi, and radiation, have been shown to influence gene methylation across the
lifespan (Ho et al., 2012). Stress and trauma have also been implicated as a trigger for
epigenetic interactions with promoter regions on genes (Ho et al., 2012; Logue et al.,
2016; Wolf et al., 2016). Psychopathology is implicated as another factor that can
influence DNA methylation (O’Donnell & Meaney, 2020; Wolf et al., 2019;
Zheleznyakova et al., 2016; Weder et al., 2014). Posttraumatic stress disorder severity is
associated with accelerated cellular aging and DNA methylation, which is linked to
poorer working memory capacity (Wolf et al., 2016). The apolipoprotein ε4 gene – a
hallmark risk factor for dementia that is reliably associated with accelerated age-related
cognitive decline (Ward et al., 2012) – has been shown to interact with PTSD among
U.S. military veterans, such that the synergistic effects of ε4 and PTSD on subjective
neurocognitive difficulties is two-to-four-fold the independent effect of either factor
(Averill et al., 2019). It was suggested that this interaction is the result of the
degeneration of neurocognitive-relevant brain regions associated with PTSD and ε4
(Averill et al., 2019). Furthermore, this interaction may be due to increased methylation
of the ε4 allele, which PTSD symptomatology has been shown to accelerate (Wolf et al.,
2016).
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Psychopathologies such as anxiety, depression, schizophrenia, and borderline
personality disorder are associated with methylation of the BDNF gene (Zheleznyakova
et al., 2016). Depression severity is associated with BDNF methylation in maltreated
children (Weder et al., 2014). Similarly, individuals with bipolar disorder exhibit
significantly higher rates of DNA methylation on the promoter region of the BDNF gene
than psychiatrically healthy controls (Mill et al., 2008; Zheleznyakova et al., 2016).
Likewise, veterans with PTSD exhibit higher levels of BDNF methylation (Kim et al.,
2017).
Subjective neurocognitive deficits associated with the Met allele are moderated by
depression symptoms, such that the association between the Met allele and subjective
neurocognitive deficits is modest (d = .16) unless observed in conjunction with
depressive symptoms (d = .77 Pitts et al., 2020). Specifically, veterans with significant
depressive symptoms and the Met allele reported poorer reasoning, concentration, and
processing speed abilities compared to Val/Val and/or non-depressed counterparts (Pitts
et al., 2020). Likewise, veterans with significant depressive symptoms and the Met allele
performed poorer on objective working memory and visual learning tasks than Val/Val
and/or non-depressed counterparts (Pitts et al., 2020).
One study has examined the unique and interactive effects of the Met allele and
PTSD on neurocognitive functioning (Mestrovic et al., 2020). Findings suggested that, in
a sample of 315 Croatian military veterans, the Met allele was significantly associated
with poorer visual short-term memory and visual object manipulation performance on the
Rey-Osterrieth Complex Figure Test among veterans with PTSD, but not among veterans
without PTSD (Mestrovic et al., 2020). To our knowledge, no studies have replicated
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these findings or examined the interactive effects of the Met allele and PTSD on other
objective measures of neurocognitive functions (e.g., visual learning and attention) or
subjective neurocognitive functioning. This is important given that subjective
neurocognitive functioning may be more strongly associated with clinically significant
neurocognitive impairment and decline than objective measures (Hess et al., 2020;
Savard & Ganz, 2016; Pietrzak et al., 2015; Waldorff et al., 2012). Additionally, the
study published on the effects of the Met allele and PTSD on neurocognitive functioning
did not conduct contrasts evaluating the effects of PTSD split by Met allele carrier status
(Mestrovic et al., 2020). Exploring this addresses an important gap, because previous
literature suggests that the Met allele may influence the etiology, maintenance, and
treatment of PTSD symptomatology (Bruenig et al., 2016; Felmingham et al., 2013; Li et
al., 2016; Malikowska-Racia & Salat, 2019; Zhang et al., 2014; Zhang et al., 2016).
Similarly, it is possible that the Met allele may influence the impact of PTSD on
neurocognitive functioning.
Current Study
The proposed study aims to examine the main and interactive effects of the Met
allele and probable past-month PTSD on objective and subjective neurocognitive
functions using data from the 2011 National Health and Resilience in Veterans Study
(NHRVS; Pietrzak, 2011). Exploratory analyses will examine these effects on specific
measures of objective (processing speed, attention, visual learning, and working memory)
and subjective (confusion, attention, memory, reasoning, concentration, and psychomotor
speed) neurocognitive functions. It is hypothesized that there will be a significant
association between probable PTSD and neurocognitive functioning, such that
individuals reporting probable PTSD will perform poorer on neurocognitive functioning
8

tasks and report poorer neurocognitive functioning than those not reporting probable
PTSD. It is also hypothesized that there will be a significant association between BDNF
SNPs and neurocognitive functioning, such that Met carriers will perform poorer on
neurocognitive functioning tasks and report poorer neurocognitive functioning than nonMet carriers. It is also hypothesized that BDNF SNPs and probable PTSD will interact
such that the effect of the Met allele on objective and subjective neurocognitive
functioning will be greater for those reporting probable PTSD relative to those not
reporting probable PTSD. Lastly, it is hypothesized that the effect of PTSD on objective
and subjective neurocognitive functioning will be greater for Met allele carriers relative
to Val homozygote counterparts.

CHAPTER 2. METHODS
Procedure
The NHRVS was approved by the Human Subjects Subcommittee of the Veterans
Affairs Connecticut Healthcare System and Office of Research & Development. Data
from the NHRVS were drawn from KnowledgePanel, a survey research panel
representing households with or without telephone or internet access (GfK Knowledge
Networks, Menlo Park, California, U.S.A.); participants were provided with computer
and internet access to participate if they could not provide their own. GfK Knowledge
Networks uses probability-based sampling of household addresses from the U.S. Postal
Service’s Delivery Sequence File, which improves population coverage. GfK Knowledge
Networks operates an incentive program for research participation. Participants of the
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NHRVS were provided with 50,000 points, which is equal to 50 USD for participation.
All participants provided informed consent before completing any study procedures.
Participants completed a large battery of questionnaires, including those used for
the present analyses. This was followed by the Cogstate Brief Battery (Cogstate Inc.,
Melbourne, Australia). After completing the Cogstate Brief Battery, the participants were
debriefed electronically. A subset of participants was selected to participate in genetic
testing. Participants who consented to genetic testing were sent Oragene DNA (OG-250)
kits and instructed to follow manufacture directions.
Participants
Participants were included in the analyses if they participated in the first wave of
the NHRVS collected in 2011 and completed the THS (Carlson et al., 2011), PCL-IV-S
(Weathers et al., 1993), CogState Brief Battery (Cogstate Inc., New Haven, CT, USA),
the MOS-Cog (Stewart et al., 1992) and DNA testing. The sample consists of 1,244
Caucasian/European American U.S military veterans who were recruited as part of the
NHRVS in 2011 (total NHRVS n = 3157). See Table 2.1 for full sample characteristics.
Post-stratification weights were applied based on the population demographic distribution
of U.S. Veterans (age, education, metropolitan area, and Census region) in the GfK
Knowledge survey panel (GfK Knowledge Networks, Menlo Park, California, USA) and
adjusted to align with U.S. Census data.
Measures
Trauma History Screen. Trauma histories were assessed using the Trauma
History Screen (THS; Carlson et al., 2011). The THS is a 14-item self-report measure of
potential Diagnostic and Statistical Manual-IV (DSM-IV; American Psychiatric
Association, 1994) criterion A1 traumatic events. The THS asks each respondent to
10

indicate whether a listed traumatic event was experienced or directly witnessed (“yes” or
“no”), and to mark the number of times each endorsed event happened. THS exhibited
high levels of one-week test-retest reliability (r = .93) for detecting trauma (Carlson et al.,
2011). Additionally, the THS demonstrated convergent validity when compared to other
validated trauma questionnaires, such as the Traumatic Events Questionnaire (r = .76;
Carlson et al., 2011). Cumulative trauma load on the THS is calculated by summing the
number of lifetime DSM-IV criterion A1 traumatic events and the number of times each
endorsed event happened.
Posttraumatic Stress Disorder Checklist. To assess probable PTSD symptoms,
the past-month DSM-IV version of the PTSD Checklist-Specific version (PCL-IV-S;
Weathers et al., 1993) was administered. The PCL-IV-S is a 17-item Likert-like selfreport measure of DSM-IV PTSD symptom severity. Item’s responses range from 1 –
“Not at all” to 5 – “Extremely”. A continuous PTSD symptom severity score is computed
by summing all items. The PCL-IV-S was administered to all participants who endorsed
at least one traumatic event on the THS. Participants were instructed to answer PCL-IV-S
questions concerning their most severe traumatic experience endorsed on the THS. A
score of 17 was imputed for participants who did not endorse at least one traumatic event
on the THS. The total score of the PCL-IV-S displays convergent validity with other
gold-standard measures of PTSD severity such as the Clinician-Administered PTSD
Scale for DSM-IV (r = .79, p < .001) and the Mississippi Scale for Combat-related PTSD
(r = .90, p < .001; Keen et al., 2008). The PCL-IV-S total score has also demonstrated
high test-retest reliability one hour following the initial assessment (r = .92, p < .001), at
a one week interval (r = .88, p < .001), and at a two week interval (r = .68, p < .001;
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Ruggiero et al., 2003). A cut-off score of 35 on the PCL-IV-S yields a sensitivity of .71
and a specificity of .84 for the detection of PTSD in the general population (Walker et al.,
2002).
Mini International Neuropsychiatric Interview. The Mini International
Neuropsychiatric Interview for DSM-IV (MINI) was adapted for self-report and used to
assess past-month major depressive disorder and lifetime alcohol abuse and drug abuse
disorders (Sheehan et al., 1998). The major depressive disorder module of the clinicianadministered MINI yields a sensitivity of .77 and a specificity of .79 in the detection of
current major depressive disorder (Sheehan et al., 1998). The substance use modules of
the clinician-administered MINI yield a sensitivity of .89 and .69 and a specificity of .93
and .99 to detect lifetime alcohol use disorder and lifetime substance use disorder,
respectively (Sheehan et al., 1998).
Medical Outcomes Study – Cognitive Functioning Scale. To assess subjective
past-month neurocognitive functioning, the Medical Outcome Study – Cognitive
Functioning Scale (MOS-Cog; Stewart et al., 1992) was administered. The MOS-Cog is a
6-item scale that assesses subjective neurocognitive dysfunction over the past month.
Each of the six questions on the MOS-Cog assesses a domain of neurocognitive
functioning over the past-month: memory (i.e., forgetfulness), reasoning, attention,
confusion, psychomotor speed, and concentration. Responses use a Likert-type scale that
ranges from 0 “All of the time” to 6 (“None of the time”). Scores on the MOS-Cog
predict Trail Making Test scores (Revicki, Chan, & Gevirts, 1998) and are moderately
correlated with objective psychomotor speed (i.e., letter-digit substitution test), attention
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(i.e., concept shifting test), and memory performance (i.e., visual-verbal learning test;
Klein et al., 2002).
Cogstate Brief Battery. The Cogstate Brief Battery is a computerized
neuropsychological battery developed by Cogstate Inc. (Cogstate Inc., Melbourne,
Australia) used to assess four neurocognitive domains: processing speed, attention, visual
learning, and working memory (Darby et al., 2012). The Cogstate Brief Battery consists
of four tests administered in a fixed order: Detection Test, Identification Test, One Card
Learning Test, and the One Back Test. Prior to each Cogstate Brief Battery test,
participants were given instructions and completed a practice trial. On every trial of each
test, a playing card stimulus is presented in the center of the computer screen. Participants
are occasionally prompted to respond to questions about these cards. Questions and
responses vary by test, as do the values, color, and suit of each card.
To assess processing speed, the Detection Test was used. In this test, the
participants are instructed to attend to a single playing card in the center of the screen.
Occasionally, the card will turn over and reveal a “joker” and participants are instructed
to respond to the question: “Has the card turned over?” as quickly as possible.
Participants indicate “K” (yes) with a single keypress. This test continues until 25 correct
responses are made or two minutes elapses. To assess attention, the Identification Test
was used. In this test, participants are instructed to respond to the question “Is the card
red?” as quickly as possible. Participants indicate “K” (yes) or “D” (no) with a keypress.
Red and black “joker” cards are displayed in equivalent numbers in random order. This
test proceeds until 35 correct answers have been recorded or the maximum time (two
minutes) is reached.
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On the Detection Test and the Identification Test, the primary measure is response
time. The response time on the Identification Test and Detection Test are measured in
milliseconds. Scores on reaction time tests were inverted, such that lower scores are
indicative of poorer neurocognitive functioning. Additionally, reaction time scores were
transformed using a logarithmic base 10 (log10) to account for the negatively skewed
distribution values (Lim et al., 2012). This transformation helps mitigate violations of the
assumption of normality for most statistical tests.
To assess visual learning, the One Card Learning Test was used. In this test,
participants are instructed to attend to the card presented and respond to “Have you seen
this card before in this task?” Participants indicate “K” (yes) or “D” (no) with a keypress.
The cards presented are non-joker playing cards. To assess working memory, the OneBack Test is used. In this test, participants are instructed to attend to the card in the center
of the screen and respond to “Is this card the same as that on the immediately previous
trial?” Participants indicate “K” (yes) or “D” (no) with a keypress. Although specific
keys were identified during each of the test instructions, keys that surrounded the “K”
key (e.g., U, I, O, J, L, M, “,” and “.” keys) were sensitive to “yes” responses and the
keys that surrounded the “D” key (e.g., W, E, R, S, X, F, V, and C keys) were sensitive to
“no” responses.
Forty-two cards are shown in the One Card Learning Test and the One-Back Test.
Target stimuli appear on 50% of the trials. Both tasks present three blocks of 14 cards
and a block is discontinued if three minutes pass. Visual learning is measured by the
proportion of correct answers, which is transformed using an arcsine square root.
Working memory is measured by the proportion of correct answers and the response
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time, which are transformed using an arcsine square root and logarithmic base 10,
respectively.
The Cogstate Brief Battery has shown utility for detecting mild neurocognitive
impairment in aging populations (Fredrickson et al., 2010). The total score of each test is
automatically transformed to be normally distributed and is then converted into a z-score.
Z-scores from each test can also be combined to compute an overall composite score that
represents overall neurocognitive functioning. Scores on the Cogstate Brief Battery are
stable up to a year after the initial assessment, as indicated by high intraclass correlations
(ICC’s = .79 - .91) between test administrations (Fredrickson et al., 2010). Scores on the
Cogstate Brief Battery do not differ when participants were supervised or unsupervised
by a research assistant (Cromer et al., 2015).
The Cogstate Brief Battery tests show strong convergent validity with traditional
neuropsychological tests (Maruff et al., 2009). Detection Test scores are correlated with
scores on measures of processing speed such as the grooved pegboard task (r = .81, p <
.001; Maruff et al., 2009). Identification Test scores are correlated with scores on
measures of attention such as the Trail Making Test (r = .78, p < .001; Maruff et al.,
2009). One-Back Test scores are correlated with scores on measures of working memory
such as the Symbol Digit Modalities Test and the Wechsler Memory Scale spatial span
task (r’s = .80 - .81, p’s < .01; Maruff et al., 2009). Lastly, One Card Learning Test
scores are correlated with scores on measures of visual memory such as the Brief Visual
Memory Test and the Rey Complex Figure Test (r’s = .69 - .83, p’s < .01; Maruff et al.,
2009). The Cogstate Brief Battery tests also demonstrated adequate discriminant validity
when compared to other neurocognitive tasks that measure different functions. The
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Detection Test and Identification Test were not significantly correlated to measures of
memory such as the Brief Visual Memory Test (r’s = .04 - .17, p’s > .01). Additionally,
the One-Back Test and the Visual Learning Test scores were not correlated with
measures of attention such as grooved pegboard task scores (r’s = .13 - .17, p’s > .01;
Maruff et al., 2009). There is overlap between the Cogstate Brief Battery tests, where
different battery tests are correlated with the same validated neuropsychological test. For
example, both the Identification Test and the Detection Test scores are both highly
correlated with the Trail Making Test (r’s = .76 - .70, p’s > .001; Maruff et al., 2009).
This pattern of multiple associations is expected, due to the extensive overlap between
neurocognitive functions (Chan et al., 2008; Friedman & Miyake, 2004; Miyake et al.,
2000).
BDNF Val66Met genotyping. To determine BDNF SNPs, saliva samples were
collected using Oragene DNA (OG-250) kits (DNA Genotek, Ontario, Canada). All
subjects recruited were Caucasian/European to reduce genetic variance between groups.
Following directions included in the kit, participants were instructed to unscrew the
saliva collection container and begin spitting into the container. Following collection,
participants were instructed to close the container and shake for 10 seconds. Saliva
samples were shipped to DNA Genotek (Ontario, Canada) to have the DNA extracted and
genotyped. Participants were instructed to avoid eating, drinking, smoking, or chewing
gum 30 minutes prior to saliva collection to avoid degradation of the saliva samples. OG250 kits maximize DNA yield compared to other types of genetic genotyping techniques,
such as buccal swabs and blood extraction (Looi et al., 2012), and remain stable at room
temperature over eight months (Nunes et al., 2012). DNA was extracted using prepIT-
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L2P reagent (DNA Genotek, Ontario, Canada) and was genotyped with a PsychChip
GWAS array. Genotypes were called using GenomeStudio software V2011.1 and
genotyping module V1.8.4 (Illumina, San Diego, CA, USA). Principal components (PC)
for GWAS data were computed using EIGENSOFT (Price et al., 2006) based on a
common set of SNPs with Hapmap3, which were in low linkage disequilibrium with one
another. Due to manufacturer protocol, outliers from the genetic data (95 subjects) were
automatically discarded from the PC analysis. Outliers were defined as individuals whose
ancestry was at least three standard deviations from the mean on the two largest PCs.
CHAPTER 3. ANALYTIC APPROACH
All statistical analyses were completed with SPSS Software Version 26
(International Business Machines Corporation, Armonk, NY, USA). PCL-IV-S scores
were dichotomized – probable PTSD (PCL-IV-S ≥ 35) and no probable PTSD (PCL-IV-S
< 35) – due to severe positive skew of PCL-IV-S scores in the present sample (Figure 1).
The main effect of the Met allele was dichotomized by contrasting Met+ veterans
(Val66Met and Met66Met) with Met- veterans (Val66Val). Val66Met and Met66Met
groups are commonly combined due to the low base rate of Met66Met (Martin et al.,
2018; Teo et al., 2014; Vulturar et al., 2016). Furthermore, in the present sample, only
four participants would be included in the Met66Met and PTSD group (n = 4). There was
no relationship between probable PTSD status and Met allele carrier status (X2 = .663, p =
.415) in this sample. Descriptive statistics such as mean scores and standard deviations of
Cogstate Brief Battery and MOS-Cog scores were calculated for the entire sample and for
PTSD (PCL-IV-S ≥ 35 and PCL-IV-S < 35) and BDNF SNP (Met carrier and non-Met
carrier) sub-groups.
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Post-stratification weights were applied to statistical analyses based on the
population demographic distribution of U.S. veterans (age, education, metropolitan area,
and Census region) in the GfK Knowledge survey panel (GfK Knowledge Networks,
Menlo Park, California, USA) and then adjusted to align with U.S. Census data.
Hypotheses were tested with multivariate analyses of covariance (MANCOVA). The
models included BDNF SNP, probable PTSD, and their interaction term as fixed effects,
age, sex, highest education level (dichotomized into less than high school and some
college or higher), income (dichotomized into annual household income of 59,999 or less
and 60,000 or more), probable current major depressive disorder, probable lifetime
alcohol or substance use disorder, military combat exposure, and cumulative trauma load
as covariates. Covariates were selected due to their association with neurocognitive
functioning (Boals & Banks, 2012; Bruijnen et al., 2019; Hooren et al., 2007; Leibovici
et al., 1996; Martindale et al., 2017; Pitts et al., 2020; Weiss, 2003). Each of the Cogstate
Brief Battery tests (Detection Test, Identification Test, One Card Learning Test, and OneBack Test) were entered as dependent variables for the first MANCOVA and each
question on the MOS-Cog (psychomotor speed, attention, confusion, concentration,
reasoning, and memory) were be entered as dependent variables for the second
MANCOVA. Alpha level was set at .01 to control for type I error rate.
Post-hoc MANCOVAs were conducted by splitting the sample by probable PTSD
status and by splitting the sample by Met allele carrier status to probe significant
interactive effects. Similarly, post-hoc analyses of covariance (ANCOVA) were
conducted after splitting the sample to probe significant main and interaction effects of
probable PTSD and Met allele carrier status on individual objective neurocognitive
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functions – attention, processing speed, visual learning, and working memory and
individual domains of subjective neurocognitive functions – psychomotor speed,
attention, confusion, concentration, reasoning, and memory.
A multivariate analysis of variance sensitivity power analysis (MANOVA) in
G*Power (Faul et al., 2007) was conducted to determine the effect size needed to reject
the null hypotheses for 2 main effects and one interactive effect. Given the sample size (n
= 1,244), desired power (.9), number of groups (4), number of predictors (6), and max
number of response variables (6), a small effect size (d = .1) would be required to detect
statistically significant (α = .01) main and interaction effects.
Missing data were multiply imputed using Markov Chain Monte Carlo
algorithms. Item-level imputation required at least 50% available data for imputation.
Outliers were identified using Mahalanobis Distance for each dependent variable.
Mahalanobis Distance values were compared to a chi-square distribution with degrees of
freedom equal to the number of factors (k = 2). Any participant with a p-value below .001
was discarded from the analysis. In total, 93 participants were identified as outliers on
either the MOS-Cog and/or the Cogstate Brief Battery and discarded from the analysis.
Participants with probable PTSD were more likely to be outliers than individuals without
probable PTSD (p < .01). There was no relationship between BDNF SNPs and outlier
status.
There are four assumptions for the MANCOVA: independent observations,
multivariate normality, multicollinearity, homogeneity of covariance. The assumption of
independent t observations is met because the data are cross-sectional and betweensubjects. Further, each participant was only counted as one observation as ensured by the
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GfK Knowledge Survey panel (GfK Knowledge Networks, Menlo Park, California,
USA). Kolmogorov-Smirnov Tests of Normality revealed that all dependent variables
were non-normal (p < .01), therefore multivariate normality cannot be assumed. Bivariate
correlations were conducted to evaluate multicollinearity between MOS-Cog questions
(r’s = .49 - .81). Bivariate correlations were also conducted to evaluate multicollinearity
between individual Cogstate tests (r’s = .07 - .59). Utilizing the multicollinearity cut-off
of .8 as suggested in the literature (Berry & Feldman, 2006), all dependent variables were
deemed non-multicollinear except for subjective attention and concentration (r = .81).
Box’s Test of Equality of Covariance was conducted to test for homogeneity of
covariance. Because Box’s Test of Equality of Covariance was (p < .001) for both
MANCOVAs, the covariance matrices of the dependent variables are not equal across
groups. Because there were violations of the assumptions of both the assumption of
multivariate normality and the assumption of homogeneity of covariance, Pillai’s Trace
was interpreted for all multivariate effects.
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Table 1. Sociodemographic and Psychiatric Characteristics (n [Weighted %] or Weighted M [SD])
PTSD PTSD +
Met Met +
Total n
1113 (89.4%)
131 (10.6%)
860 (69.1%)
384 (30.9%)
Genetic Characteristics
Met 770 (69.2%)
90 (68.8%)
Met +
343 (30.8%)
41 (31.2%)
Sociodemographic
Age
62.7 (13.8)
53.9 (16.7)
62.4 (14.5)
60.4 (14.0)
Male
1029 (92.5%)
116 (88.1%)
794 (92.4%)
351 (91.4%)
Female
83 (7.5%)
16 (11.9%)
66 (7.6%)
33 (8.6%)
Married/cohabitating
868 (78.0%)
77 (58.6%)
656 (76.3%)
289 (75.2%)
Annual income ≥ 60,000
525 (47.2%)
29 (21.9%)
379 (44.1%)
175 (45.6%)
Education level
High school or less
345 (31.0%)
48 (36.7%)
274 (31.9%)
119 (31.0%)
Some college
385 (34.6%)
59 (44.9%)
308 (35.8%)
136 (35.4%)
Bachelor’s degree or higher
383 (34.4%)
24 (18.4%)
278 (32.3%)
129 (33.6)
Clinical characteristics
Cumulative trauma
3.0 (2.4)
6.3 (3.2)
3.3 (2.7)
3.3 (2.7)
Probable lifetime AUD/DUD 233 (20.9%)
60 (45.5%)
209 (24.3%)
84 (21.8%)
Probable current MDD
139 (12.5%)
77 (58.2%)
146 (17.0%)
70 (18.2%)
Military characteristics
Years in military
7.2 (7.7)
6.2 (6.5)
7.0 (7.6)
7.3 (7.5)
Combat veteran
337 (30.4%)
64 (48.4%)
294 (34.3%)
107 (27.8%)

Full Sample
1244
61.8 (14.3)
1145 (92.1%)
99 (7.9%)
945 (75.9%)
554 (44.5%)
393 (31.6%)
444 (35.7%)
407 (32.7%)
3.3 (2.7)
293 (23.5%)
216 (17.3)
7.1 (7.6)
401 (32.3%)

Note. Probable PTSD defined as PCL-IV-S ≥ 35. AUD = alcohol use disorder; DUD = drug use disorder; MDD = major
depressive disorder; PTSD = posttraumatic stress disorder

Figure 1. Distribution of PCL-IV-S Scores Within the Entire Sample

Note. PCL-IV-S = Posttraumatic Stress Disorder Checklist (DSM-IV Version) – Specific
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CHAPTER 4. RESULTS
Cogstate Brief Battery
A MANCOVA exploring the impact of probable PTSD and Met allele carrier
status on the Cogstate Brief Battery revealed a significant effect of PTSD on overall
objective neurocognitive functioning [F(5, 1064) = 4.237, p = .001, ηp2 = .020], such that
individuals with probable PTSD displayed poorer neurocognitive functioning (M = -.106,
SE = .072) than individuals without probable PTSD (M = .097, SE = .020). A significant
effect of Met allele carrier status on overall objective neurocognitive functioning [F(5,
1064) = 3.802, p = .002, ηp2 = .018] was observed, such that individuals with the Met
allele displayed poorer neurocognitive functioning (M = -.020, SE = .057) than
individuals without the Met allele (M = .012, SE = .042). A significant Met*PTSD
interaction on overall objective neurocognitive functioning was observed [F(5, 1064) =
6.215, p < .001, ηp2 = .028]. Follow-up ANCOVAS revealed that the Met*PTSD
interaction was significant for attention performance [F(1, 1068) = 9.683, p = .002, ηp2 =
.009].
To probe the significant Met*PTSD interaction, the sample was split by probable
PTSD status, then a MANCOVA was conducted to examine the main effects of the Met
allele among veterans with and without probable PTSD. A significant main effect of Met
allele carrier status suggested that the Met allele impacted objective neurocognitive
functioning among individuals with probable PTSD [F(5, 74) = 3.729, p = .008, ηp2 =
.168]. Among individuals with probable PTSD, Met allele carriers displayed poorer
neurocognitive functioning (M = -.107, SE = .84) than non-Met carriers (M = .035, SE =
.060). Although the main effect of Met allele carrier status was not significant among
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individuals without probable PTSD [F(5, 980) = 2.975, p = .01, ηp2 = .013], it was
trending in the opposite direction.
The sample was also split by Met allele carrier status, then MANCOVA were
conducted to examine the main effects of PTSD among veterans with and without the
Met allele. Significant main effects of PTSD suggested that PTSD impacted objective
neurocognitive functioning among Met allele carriers [F(5, 312) = 3.318, p = .006, ηp2 =
.050] and non-Met allele carriers [F(5, 740) = 10.548, p < .001, ηp2 = .067], such that
probable PTSD status was similarly associated with poorer neurocognitive functioning in
both groups. Among individuals with the Met allele, individuals with probable PTSD
displayed poorer neurocognitive functioning (M = -.227, SE = .108) than individuals
without PTSD (M = .148, SE = .030). Similarly, among individuals without the Met
allele, individuals with probable PTSD displayed poorer neurocognitive functioning (M =
-.022, SE = .088) than individuals without PTSD (M = .061, SE = .023). See Figure 2.
After splitting the sample by probable PTSD status, follow-up ANCOVAs
suggest that the Met allele was not significantly associated attention functioning in
individuals with probable PTSD [F(1, 983) = 1.629, p = .115, ηp2 = .003] or without
probable PTSD [F(1, 77) = 3.933, p = .012, ηp2 = .078]. After splitting the sample by Met
allele carrier status, follow-up ANCOVAs suggest that PTSD was not significantly
associated with attention functioning in individuals with the Met allele [F(1, 316) =
5.113, p = .024, ηp2 = .016] or without the Met allele [F(1, 744) = 4.497, p = .034, ηp2 =
.006]. See Table 2.
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Medical Outcomes Study – Cognitive Functioning Scale
A MANCOVA exploring the impact of probable PTSD and Met allele carrier
status on the MOS-Cog revealed a significant effect of PTSD on overall subjective
neurocognitive functioning [F(6, 1063) = 23.629, p < .001, ηp2 = .118], such that
individuals with probable PTSD reported poorer neurocognitive functioning (M = -.751,
SE = .085) than individuals without probable PTSD (M = .172, SE = .024). A significant
effect of Met allele carrier status on overall subjective neurocognitive functioning [F(6,
1063) = 7.683, p < .001, ηp2 = .042] was observed, such that Met allele carriers reported
poorer neurocognitive functioning (M = -.345, SE = .068), than non-Met carriers (M = .234, SE = .50). A significant Met*PTSD interaction on overall subjective neurocognitive
functioning was observed [F(6, 1063) = 5.310, p < .001, ηp2 = .029]. Follow-up
ANCOVAS revealed that the Met*PTSD interaction was significant for psychomotor
speed [F(1, 1068) = 14.979, p < .001, ηp2 = .014] and concentration F(1, 1068) = 7.526, p
= .006, ηp2 = .007].
To probe the significant Met*PTSD interaction, the sample was split by probable
PTSD status, then a MANCOVA was conducted to examine the main effects of the Met
allele among participants with and without probable PTSD. A significant main effect of
Met allele status suggested that, among individuals with probable PTSD [F(6, 72) =
3.730, p = .003, ηp2 = .237], Met carriers reported poorer subjective neurocognitive
functioning (M = -.988 SE = .186) compared to non-Met carriers (M = -.830, SE = .133).
There was not a significant effect of the Met allele on subjective neurocognitive
functioning among individuals without probable PTSD [F(6, 978) = 1.515, p = .170, ηp2 =
.009].
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The sample was also split by Met allele carrier status, then a MANCOVA was
conducted to examine the main effects of PTSD among veterans with and without the
Met allele. Significant main effects of PTSD among non-Met allele carriers [F(6, 739) =
10.423, p < .001, ηp2 = .078] and Met allele carriers [F(6, 311) = 15.892, p < .001, ηp2 =
.235] suggested that, regardless of Met allele status, subjective neurocognitive
functioning was poorer for individuals with probable PTSD than for those without;
however, the effect size among Met allele carriers was nearly three times larger. Among
individuals with the Met allele, those with probable PTSD displayed poorer
neurocognitive functioning (M = -.948, SE = .149) than those without PTSD (M = .203,
SE = .041). Similarly, among individuals without the Met allele, those with probable
PTSD displayed poorer neurocognitive functioning (M = -.599, SE = .026) than those
without PTSD (M = .148, SE = .026). See Figure 3.
After splitting the sample by probable PTSD status, follow-up ANCOVAs
suggest that among veterans without probable PTSD, the Met allele was not significantly
associated with psychomotor speed [F(1,983) = .061, p = .805, ηp2 < .001] or
concentration [F(1, 983) = .003, p = .959, ηp2 < .001]. Among individuals with probable
PTSD, the Met allele was significantly associated with subjective psychomotor speed
[F(1, 77) = 8.111, p = .006, ηp2 = .095], such that individuals with probable PTSD and the
Met allele reported poorer psychomotor speed than individuals with probable PTSD but
without the Met allele (Table 3). After splitting the sample by Met allele carrier status,
ANCOVAs revealed that, among non-Met carriers, probable PTSD was significantly
associated with concentration [F(1, 744) = 34.479, p < .001, ηp2 = .044], and psychomotor
speed [F(1, 744) = 26.227, p < .001, ηp2 = .034], such that individuals without the Met
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allele and with probable PTSD reported poorer psychomotor speed and concentration
than individuals without the Met allele and without probable PTSD (Table 3). Similarly,
among Met carriers, probable PTSD was significantly associated with concentration [F(1,
316) = 53.212, p < .001, ηp2 = .144] and psychomotor speed [F(1, 316) = 58.705, p <
.001, ηp2 = .157], such that individuals with the Met allele and with probable PTSD
reported poorer psychomotor speed and concentration than individuals with the Met
allele and without probable PTSD (Table 4.2).
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Table 2. Estimated Marginal Means of Multivariate Analysis of Covariance on Objective Neurocognitive Functioning

Processing Speed

Attention

Visual Learning

Working Memory Working Memory
Accuracy
Reaction

M

SE

M

SE

M

SE

M

SE

M

SE

PTSD -, Met -

.094

.028

.040

.031

.000

.037

.100

.033

.079

.033

PTSD -, Met +

.164

.043

.130

.048

.128

.057

.021

.051

.018

.050

PTSD +, Met -

-.168

.103

.270

.116

-.050

.138

-.388

.123

-.269

.122

PTSD +, Met +

.042

.139

-.239

.115

-.313

.186

-.297

.166

-.220

.164
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Note. Results adjusted for cumulative trauma load, sex, income, educational attainment, probable current major depressive disorder,
probable lifetime alcohol use disorder or drug use disorder, and military combat exposure. Means are displayed as Z-scores.
M = mean, SE = standard error, PTSD = posttraumatic stress disorder

Table 3. Estimated Marginal Means of Multivariate Analysis of Covariance on Subjective Neurocognitive Functioning
Psychomotor
Speed

Memory

Reasoning

Concentration

Confusion

Attention

29

M

SE

M

SE

M

SE

M

SE

M

SE

M

SE

PTSD -, Met -

.173

.025

.141

.031

.107

.027

.187

.027

.194

.024

.174

.027

PTSD -, Met +

.184

.036

.168

.048

.190

.041

.188

.041

.194

.036

.243

.042

PTSD +, Met -

-.353

.094

-.520

.116

-.389

.100

-.459

.099

-.440

.088

-.633

.102

PTSD +, Met +

-.955

.127

-.560

.156

-.179

.135

-.912

.133

-.718

.119

-.797

.138

Note. Results adjusted for cumulative trauma load, sex, income, educational attainment, probable current major depressive disorder,
probable lifetime alcohol use disorder or drug use disorder, and military combat exposure. M = mean; SE = standard error; PTSD =
posttraumatic stress disorder

Figure 2. Estimated Marginal Means of PTSD and the Met Allele on Overall Objective
Neurocognitive Functioning.

**

*

* = p < .01, ** = p < .001
Note. PTSD = posttraumatic stress disorder, SE = standard error
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Figure 3. Estimated Marginal Means of PTSD and the Met Allele on Overall Subjective
Neurocognitive Functioning

**
*

* = p < .01, ** = p < .001
Note. PTSD = posttraumatic stress disorder, SE = standard error
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CHAPTER 5. DISCUSSION
This study examined the effects of the SNPs on the BDNF gene and probable
PTSD on objective and subjective neurocognitive functioning in a nationally
representative sample of U.S. military veterans. Met allele carrier status and probable
PTSD interacted, such that the effects of the Met allele on neurocognitive functioning are
dependent on the presence of PTSD, such that individuals with the Met allele and
probable PTSD display poorer neurocognitive functioning relative to non-PTSD
counterparts and/or non-Met carriers. Additionally, the impact of PTSD on
neurocognitive functioning was significant regardless of Met allele carrier status, but the
impact of PTSD on subjective neurocognitive functioning was three times greater among
Met allele carriers than non-Met carriers.
The present results replicate the previously reported interaction between PTSD
and the Met allele on neurocognitive functioning (Mestrovic et al., 2020) and extend the
literature by employing a measure with improved psychometric properties and by
exploring domains not assessed by the Rey-Osterrieth Complex Figure (i.e., attention and
processing speed). Mestrovic and colleagues found that Val66Val served a protective
function in veterans with PTSD with short-term memory and visual object manipulation
compared to veterans with Met allele and PTSD (Mestrovic et al., 2020). Similarly, the
present study found that the Val66Val served a protective function; however, planned
contrasts suggest this effect was not significantly confined to a specific neurocognitive
domain. The present data suggest that PTSD and the Met allele interact to negatively
impact overall neurocognitive functioning broadly. Additionally, this study extends the
literature by examining the differential impact of PTSD on neurocognitive functioning
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depending on the presence or absence of the Met allele, which has not been previously
reported. Lastly, this study extends the literature by examining the interactive impact of
the Met allele and PTSD on objective and subjective neurocognitive functioning
concurrently. Statistically significant objective neurocognitive deficits do not always
equate to clinically significant deficits in neurocognition-relevant domains of functioning.
Small effect size deficits in objective neurocognitive functioning have low clinical
significance unless accompanied by subjective reductions (Savard & Ganz, 2016). By
evaluating both objective and subjective neurocognitive functioning concurrently, the
current study was able to detect salient neurocognitive concerns among the U.S. veteran
population.
Methylation of the CpG islands on the Met allele is common among individuals
with psychopathology (O’Donnell & Meaney, 2020, Zheleznyakova et al., 2016) and has
been observed in individuals with PTSD (Wolf et al., 2019). It is hypothesized that the
stressors associated with psychopathology are frequent and severe enough to demethylate
stress-related genes and methylate genes involved in higher-order processes (Ho et al.,
2012). If a gene associated with neural plasticity or higher-order thinking is methylated
due to stress, it is unlikely that the gene will demethylate until the individual is removed
from the stressor (Ho et al., 2012). Therefore, not producing BDNF due to stress-related
methylation of BDNF CpG islands, would likely result in reductions in neurocognitive
functioning beyond the effect of SNPs alone. As such, it is possible that the interaction
between current probable PTSD and the Met allele on subjective and objective
neurocognitive function is due to methylation of the CpG island on the Met allele. The
present study did not assess for methylation. As such, future research should explore the
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possibility of a mediated moderation, where the interaction between the Met allele and
PTSD on neurocognitive functioning is itself mediated by BDNF CpG island
methylation. Other epigenetic mechanisms may explain the current results. For example,
microRNA expression responds to environmental changes (e.g., stress) and can impact
the expression of a gene (Ho et al., 2012). MicroRNA has been implicated as an
important regulator of several brain processes, such as neurogenesis, synaptic plasticity,
and neurocognitive functioning (Luoni & Riva, 2016; Xu, Hsu, Karayiorgou, & Gogos,
2012). Gathering data on DNA methylation and microRNA functioning could better
inform the relationship between PTSD and the Met allele on subjective and objective
neurocognitive functioning.
Significant interactions between PTSD and the Met allele on neurocognitive
functioning may also be driven by mutual degeneration of neurocognition-relevant brain
regions and stunted neural plasticity. The Met allele is theorized to impact neurocognitive
functioning because of its detrimental effect on BDNF secretion (Kennedy et al., 2015).
Secretion of BDNF is crucial to neurocognitive functioning because it regulates longterm potentiation and synaptic plasticity (Bramham & Messaoudi, 2005; Calabrese et al.,
2014; Lu et al., 2005). Additionally, BDNF secretion is associated with prefrontal grey
matter volume (Pezawas et al., 2004), which can influence the ability to regulate
neurocognitive abilities (Depue et al., 2010). As such, if lower levels of BDNF are
secreted in the prefrontal cortex because of the Met allele, it could result in poorer
neurocognitive functioning. PTSD is similarly associated with lower prefrontal grey
matter volume (Holmes et al., 2018). The interactive impact of PTSD and the Met allele
may be the result of concurrent volumetric grey matter reductions and reduced neural
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plasticity, which may exhibit an exacerbating effect. Future research should utilize
neuroimaging to examine neurological differences among individuals with PTSD with
and without the Met allele.
This study possesses several strengths. First, the dataset is large, and nationally
representative for Caucasian U.S. military veterans and all analyses utilized
poststratification weights to align the sample with U.S. census data. Additionally, the
findings of this study were significant after controlling for possible confounding variables
including age, sex, cumulative trauma load, income, probable past-month major
depressive disorder, military combat exposure, probable lifetime substance/alcohol use
disorder, and education level. Another strength of this study is the mean age of the
sample (M = 61.8). Not only is this age representative of U.S. military veterans, but the
older sample allows inferences to be drawn regarding characteristics that put an
individual at risk of age-related cognitive deficits.
Due to the increased birthrate following World War II and advancements in
medicine, there has been a significant shift in the age distribution in the U.S. (Shay,
2015). This age distribution shift contributed to an increase in the national median age
from 35.3 in 2000 to 38.4 in 2019 (Jordan, 2020; Meyer, 2001). U.S. military veterans
are, by comparison, much older than the general population (Eibner et al., 2015; Villa et
al., 2005). In 2000, the median age of U.S. veterans was 57 (Richardon & Waldrop,
2003). In 2020, the median age of veterans was 65 years (Vespa, 2020). A forward age
distribution shift among U.S. veterans is likely associated with an increased prevalence of
age-related neurocognitive decline among veterans (Parkar, 2015). Age-related
neurocognitive decline is a chief concern among the elderly, as it is associated with a
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diversity of adverse outcomes such as poorer quality of life and increased burden on
caretakers and family members (Harada et al., 2014; Schneider, 2001). As such, research
is needed to compare the impact of the Met allele and PTSD on neurocognitive
functioning throughout the lifespan to determine if the efforts reported herein worsen
with age. SNPs may exhibit an antagonistic pleiotropic effect; said otherwise, a gene may
offer a protective function during early life stages and become detrimental at later life
stages or vice versa. For example, the APOE e4 allele – a hallmark risk factor for
dementia – has been associated with superior verbal fluency in 6-to-15-year-olds
compared to non-e4 carriers in the same age group but is associated with significant
neurocognitive deficits later in life (Dik et al., 2001). Therefore, the possibility exists that
the effect of the Met allele on neurocognitive functioning may change throughout the
lifespan. Furthermore, the Met allele may interact with PTSD differently depending on
the age group assessed. Further research should examine a moderating effect of age on
the unique and interactive effects of PTSD and the Met allele.
One inherent weakness of this study is the poor divergent validity of the Cogstate
Brief Battery. Often, neurocognitive measures exhibit poor divergent validity, making it
difficult to separate overall neurocognitive functioning into individual domains (Chan et
al., 2008; Friedman & Miyake, 2004; Miyake et al., 2000); though this weakness is offset
by the use of MANCOVAs for hypothesis tests. In this dataset, objective attention
performance and objective processing speed performance were highly correlated (r = .59,
p < .001), likely because they are both measured in reaction time. Because attention and
processing speed are highly correlated, it is difficult to discern whether performance on
the Identification Test or the Detection Test are due to processing speed, attention, or a
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combination of the two. As such, future research may examine the interactive impact of
the Met allele and PTSD on neurocognitive functioning using a more comprehensive
battery of neurocognitive measures with stronger discriminant validity such as the
executive function battery posed by Miyake and colleagues (2000). Future research
employing such an executive function battery may provide deeper insight into exact
neurocognitive abilities affected by PTSD and the Met allele.
Another limitation of the study is that the MOS-Cog and the Cogstate Brief
Battery had non-normal distributions and heterogeneous variances. For example, the
One-Back Test exhibited a severe ceiling effect (skewness = -2.2, kurtosis = 9.1). There
were 23.7% of participants (n = 298) who received the maximum score on working
memory accuracy performance. Although the One-Back Test can be used to detect severe
working memory deficits (Maruff et al., 2009), in a relatively healthy sample the OneBack Test may not be sufficiently sensitive to detect deficits or group differences. A
similar ceiling effect was observed on each question of the MOS-Cog. As such, future
research may examine the impact of PTSD and the Met allele using more sensitive
measures such as the Subjective Cognitive Decline Questionnaire (Rami et al., 2014) for
subjective neurocognitive functioning and/or the executive functioning battery posed by
Miyake and colleagues (2000).
Another important limitation is that the data are cross-sectional, and therefore do
not allow us to conclude the directional associations among the variables assessed. As
referenced earlier, there are data suggesting that neurocognitive deficits are both risk
factors for and consequences of PTSD (Aupperle et al., 2012; Gil et al., 1990; Gilbertson
et al., 2001; Parslow & Jorm 2007; Vasterling et al., 2002). These data can suggest a
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directional relationship between the Met allele and neurocognitive deficits, given that
inheritance of the Met allele occurs prior to the presence of neurocognitive functioning or
PTSD. However, these data cannot inform the directional nature of the relationship
between PTSD and neurocognitive functioning. Further longitudinal research that
assesses genetic SNPs and neurocognitive functioning before and after trauma exposure
and PTSD could help inform causality and the direction of the interaction between PTSD
and the Met allele on neurocognitive functioning.
The current study has important implications for the treatment and prevention of
age-related cognitive decline. There are multiple modifiable factors that combat the
progression of age-related cognitive decline, such as nutrition, physical exercise, and
neurocognitive training (Andrade & Radhakrishnan, 2009). However, few studies have
observed the impact of treating psychopathology among individuals who are at risk for
accelerated age-related cognitive decline. There is some evidence that treating PTSD can
improve neurocognitive function (Jak et al., 2018). For example, a single case study
found that cognitive processing therapy improved processing speed and attention
alongside improvements in PTSD symptoms (Boyd et al., 2016). Additionally, a small
study (n = 15) found that individual trauma-focused therapy was associated with
clinically significant improvements in memory and executive functioning (Walter et al.,
2010). As such, therapeutic intervention for PTSD may eliminate the adverse effects of
the Met allele on neurocognitive functioning among individuals with PTSD. For
example, reductions in PTSD symptoms may demethylate neurocognition-relevant CpG
islands, resulting in a positive impact on neurocognitive functioning; however, further
research is needed to support this claim.
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Future studies examining the effect of the Met allele on neurocognitive
functioning should also examine other psychiatric disorders. The current study speculates
that the interaction between PTSD and the Met allele on neurocognitive functioning is
due to DNA methylation from PTSD-related stressors. Significant levels of methylation
on the BDNF gene are seen in other psychopathologies such as major depressive
disorder, schizophrenia, and borderline personality disorder (O’Donnell & Meaney, 2020;
Zheleznyakova et al., 2016). As such, other forms of psychopathology or combinations of
psychopathology can methylate the BDNF allele and display similar interactive effects on
neurocognitive functioning.
These results highlight the importance of assessing psychopathological factors
when evaluating the impact of genetic SNPs on phenotypic effects. Stress has a major
impact on gene expression which can introduce significant error when evaluating the
impact of genetics on any observable outcome (Ho et al., 2012). It is hypothesized that
studies searching for candidate gene-disease associations typically yield small effect sizes
due to unknown gene-gene interactions (Ioannidis et al., 2006). Alternatively, failed
candidate gene studies may be the result of ignoring the impact of psychopathology on
gene expression. As such, researchers should broadly assess psychopathology when
exploring the impact of a gene or SNP on neurocognitive outcomes.
CHAPTER 6. CONCLUSION
As neurocognitive dysfunction is a salient concern among aging U.S. military
veterans, it is important to understand modifiable factors that impact neurocognitive
functioning for individuals who are at risk for neurocognitive dysfunction. The present
results replicated a previously reported interaction between the Met allele and PTSD on
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objective neurocognitive functioning and extended the literature by showing a similar
interaction on subjective neurocognitive functioning in a large, nationally representative
sample of Caucasian U.S. military veterans. These results suggest that the stressors
associated with PTSD may impact BDNF allele expression, likely resulting in
downstream effects on neurocognitive functioning; however further longitudinal
epigenetic research is needed to support this inference. These results highlight the
importance of assessing psychopathology as a possible confound in genetic research.
Additionally, these results underscore the importance of assessing and treating PTSD in
individuals who are at genetic risk for neurocognitive deficits. Although modern
therapeutic intervention cannot change one’s genetic code, treating current PTSD may
reduce the impact of genetic risk factors for neurocognitive deficits.
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